A Novel, Low-Cost, Handheld, 3D Imaging System for Improved Screening of Cervical Neoplasia in Resource Limited Settings

摘要 宫颈癌是最可预防和治疗的癌症之一，这一事实反映了它的 在过去的30年里，大多数发达国家的发病率显著下降，主要是由于有效的 筛查和治疗方案。在发展中国家和社会经济条件差的地区 在发达国家，许多妇女缺乏方便的途径，无法负担得起和高质量的计划，以节省 孩子们当中.目前，全世界有超过一百万妇女患有宫颈癌。这些妇女中的大多数不 获得诊断和治疗，可以治愈他们或延长他们的生命。2012年，新增50万人以上 全世界诊断出宫颈癌病例，其中超过25万妇女死于这种疾病-- 在低收入到中等收入国家，这一比例接近90%。预计宫颈癌死亡人数将增加近 在未来10年内，如果没有适当的干预，将增加25%。新的技术发展提供了潜力， 使低收入和中等收入国家的宫颈癌综合治疗切实可行且负担得起， 缓解发达国家飞涨的医疗成本。作为回应，我们最近开发了 （通过NSF-SBIR和NIH-SBIR奖的支持）便携式，低成本，简单易用的远程医疗- 和患者友好的创新成像系统，可以帮助推进屏幕和治疗策略， 世界卫生组织倡导的宫颈癌预防。在第二阶段的研究中，我们将建立 通过一项多地点的国际研究，我们的筛选方案的可行性，并推进整体技术。

Abstract Cervical cancer is one of the most preventable and treatable forms of cancer, reflected by the fact that its incidence has significantly fallen in most of the developed world over the past 30 years, largely due to effective screening and treatment programs. In developing countries and also in socio-economic disadvantaged areas of developed countries, many women lack convenient access to affordable and high-quality programs to save their lives. Currently, more than a million women worldwide have cervical cancer. Most of these women do not have access to diagnoses and treatments that could cure them or prolong their lives. In 2012, >500,000 new cases of cervical cancer were diagnosed worldwide, and >250,000 of these women died of the disease -- nearly 90% in low- to middle-income countries. Deaths due to cervical cancer are projected to rise by almost 25% over the next 10 years without proper interventions. New technological developments offer the potential to make comprehensive cervical cancer care feasible and affordable in low- and middle-income countries, and to mitigate the skyrocketing healthcare costs in the developed world. In response, we have recently developed (through support from an NSF-SBIR and NIH-SBIR award) a portable, low-cost, simple-to-use, telemedicine- and patient-friendly innovative imaging system that can help advance toward the screen-and-treat strategy for cervical cancer prevention advocated by the World Health Organization. In this phase II study, we will establish feasibility of our screening protocols through a multisite international study and advance the overall technology.